Histone Deacetylase Inhibitors for Cancer Therapy

By Tae‐You Kim, Y. Bang, Keith D. Robertson. Epigenetics, 2006

862 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/d48c814333e3533f0be11f7a5e28313b46077d55

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications (2016, background): “These results suggest that SIRT1 may be a good therapeutic target for prostate cancer among others [91].”
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents (2015, background): “In terms of its target, vorinostat inhibits Class I, II and IV HDAC proteins, but not the NAD+-dependent Class III HDAC [45–47].”
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family (2012, background): “Deregulation of transcription as a consequence of altered protein acetylation patterns is a hallmark of cancer, a mechanism that is currently targeted by HDAC inhibitors (Lane and Chabner, 2009).”
Epigenetic Modifications as Therapeutic Targets (2010, background): “2 ), and recent clinical trials of these agents have been extensively reviewed elsewhere (see also Tables 2 and 3”
Histone Deacetylase Inhibitors: Potential in Cancer Therapy (2009, background): “1) [Bolden et al., 2006; Minucci and Pelicci, 2006; Glozak and Seto, 2007; Jones and Baylin, 2007; Rasheed et al., 2007; Xu et al., 2007; Dokmanovic et al., 2007a; Blackwell et al., 2008; Moradei et al., 2008; Shankar and Srivastava, 2008].”
Covalent histone modifications: miswritten, misinterpreted, and miserased in human cancers (2010, result): “In support, the clinical success of HDAC inhibitors in cutaneous T cell lymphoma and DNA demethylating agents in myelodysplastic syndrome offers a compelling argumen”
Histone Deacetylase Inhibitors: Overview and Perspectives (2007, background): “Clinical trials with phenylacetate have generally shown little anticancer activity (5, 51, 70).”
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer (2010, background): “Several HDAC inhibitors, such as Trichostatin A and vorinostat, have now entered clinical trials for various cancers either as single agents or in combination with targeted and conventional therapeutics (Lane and Chabner, 2009).”
HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention (2007, background): “Many pharmaceutical companies have active programs on related inhibitors that target the classical family of HDACs (for recent reviews, see Minucci and Pelicci, 2006; Marchion and Munster, 2007; Rasheed et al., 2007).”
Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. (2004, background): “Several HDAC inhibitors are now in phase I and II human trials.(2,17,18) Most of the known HDAC inhibitors have broad specificity for both class 1 and class 2 deacetylases, although some (e.”